Home / Investors / Financial corner / Press releases / THE LIAISON® SARS-COV-2 S1S2 IGG TEST IS THE FIRST TO RECEIVE THE APPROVAL FROM HEALTH CANADA

THE LIAISON® SARS-COV-2 S1S2 IGG TEST IS THE FIRST TO RECEIVE THE APPROVAL FROM HEALTH CANADA